LabCorp grew revenue despite Dx reimbursement challenges

LabCorp ($LH) grew revenue slightly but faced flat net earnings during its 2013 third quarter in the face of continued reimbursement challenges. The North Carolina diagnostics giant said net earnings hit $148.3 million during the quarter, essentially flat over the same period in 2012. LabCorp booked more than $1.46 billion in revenue, however, a 3% jump over the 2012 third quarter. LabCorp attributed the revenue results to higher testing volume and growth in its toxicology business, balanced by government payment reductions and insurance reimbursement issues involving molecular pathology codes. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.